Pregabalin Capsule
Product Images NDC 63629-8195

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8195). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636298195)

This is a description for Pregabalin Capsules. The capsules contain 50 mg of Pregabalin, USP, which is a medication used for pain relief. The instructions indicate to keep the medication out of the reach of children and store at room temperature. The NDC code for this medication is 63629-8195-01, and it comes in a bottle of 30 capsules.*

FDA Label Image

Lbl6362981952

This is a medicine package for a Lyrica 50mg capsule made by ScieGen Pharmaceuticals Inc. It contains 30 capsules with an expiration date of MM/YY. The package was prepacked by Bryant Ranck. The medicine should be stored at room temperature and kept out of reach of children. The rest of the text is not available as it contains non-English characters and errors.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

The text appears to be a chart consisting of numerical values that represent the percentage of patients who showed improvement in pain, without any further context it is difficult to determine the source, units, or additional information.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

This appears to be a chart or graph showing the percentage of patients who experienced improvement in pain levels after taking Pregabalin 160 mg for three days. The chart includes percentages ranging from 2 to 100, and there are also some numbers indicating timeframes. However, it is difficult to interpret the information without additional context or a clearer image.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

FDA Label Image

Figure 6 (Pregabalin Fig06)

The text provides a comparison of studies labeled E1, E3, and S5. The studies tested the effects of different dosages of an unspecified compound on an unknown outcome. The doses were placebo, 50mg/day, 150mg/day, 300mg/day, and 600mg/day. The phrase "statistically significant vs. placebo" suggests that the compound had a measurable effect compared to the control group.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text shows a graph comparing the percent improvement in pain from baseline in patients taking Pregabalin at 300mg and 450mg daily dose versus a placebo. The graph demonstrates that patients on Pregabalin had a higher percent of improvement in pain compared to those on a placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

The text appears to be a table displaying percentage values of the estimated number of subjects without LTR for different treatment groups over the course of several days. The treatment groups are labeled as "Progabain" and "Placebo." However, there is no further context or information to determine the study or condition being evaluated, making it difficult to provide a more specific description.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

This is a table presenting the percent of subjects improved from baseline to week 16 BOCF on Pregabalin versus Placebo treatment. There are percentage values from 100 to 280, listed in increments of 10, on the vertical axis and drug names "Pregabalin" and "Placebo" listed horizontally.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This appears to be a formula for calculating creatinine clearance (CLCT). CLCT is a measure of kidney function, and it is determined by multiplying the result of [140 - age (years)] x weight (kg) by 0.85 for female patients and 72 x serum creatinine (mg/dL).*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.